Low-dose aspirin for primary prevention

Dr Eric Topol

Disclosures

June 17, 2009

This feature requires the newest version of Flash. You can download it here.

A new meta-analysis questions the use of low-dose aspirin for the prevention of cardiovascular events. Given its current wide use, these findings are important and have far-reaching consequences. What are your thoughts?

See:

Meta-analysis questions use of aspirin in primary prevention

Antithrombotic Trialists' (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009; 373: 1849-1860.

Algra A and Greving JP. Aspirin in primary prevention: sex and baseline risk matter. Lancet 2009; 373: 1821-1822.

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as:

processing....